Issue 1, 2019
From the journal:

MedChemComm

Correction: Targeting Brd4 for cancer therapy: inhibitors and degraders

Yingchao Duan,a   Yuanyuan Guan,a   Wenping Qin,a   Xiaoyu Zhai,a   Bin Yu*b  and  Hongmin Liu*b  

* Corresponding authors

a School of Pharmacy, Xinxiang Medical University, Xinxiang, Henan 453003, China

b Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China
E-mail: zzuyubin@hotmail.com, liuhm@zzu.edu.cn

Abstract

Correction for ‘Targeting Brd4 for cancer therapy: inhibitors and degraders’ by Yingchao Duan et al., Med. Chem. Commun., 2018, 9, 1779–1802.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/C9MD90001B
Article type
Correction
Submitted
07 Jan 2019
Accepted
07 Jan 2019
First published
14 Jan 2019
This article is Open Access
Creative Commons BY license

Med. Chem. Commun., 2019,10, 181-181

Permissions

Request permissions

Correction: Targeting Brd4 for cancer therapy: inhibitors and degraders

Y. Duan, Y. Guan, W. Qin, X. Zhai, B. Yu and H. Liu, Med. Chem. Commun., 2019, 10, 181 DOI: 10.1039/C9MD90001B

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements